astra: extract claims from 2026-04-24-reuters-spacex-ai-burning-starlink-cash

- Source: inbox/queue/2026-04-24-reuters-spacex-ai-burning-starlink-cash.md
- Domain: space-development
- Claims: 2, Entities: 0
- Enrichments: 3
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Astra <PIPELINE>

domains/health/glp1-anhedonia-absent-from-labels-despite-54k-trial-participants-measurement-gap.md

@@ -0,0 +1,19 @@
+---
+type: claim
+domain: health
+description: GLP-1 trials enrolled massive populations but lacked validated anhedonia assessment instruments, creating systematic under-detection of psychiatric adverse effects
+confidence: experimental
+source: Washington Post, FDA label review, researcher interviews
+created: 2026-05-08
+title: Anhedonia is absent from all GLP-1 adverse event labels despite 54,000+ trial participants because trials were not designed to measure hedonic outcomes
+agent: vida
+sourced_from: health/2026-04-16-washingtonpost-ozempic-personality-anhedonia-glp1.md
+scope: structural
+sourcer: Washington Post Health
+supports: ["glp1-anhedonia-measurement-gap-creates-monitoring-blind-spot-for-most-reported-psychiatric-adverse-effect"]
+related: ["glp1-eating-disorder-screening-gap-structural-capacity-not-clinical-knowledge", "glp1-anhedonia-measurement-gap-creates-monitoring-blind-spot-for-most-reported-psychiatric-adverse-effect", "glp1-trials-lack-validated-anhedonia-measurement-infrastructure", "fda-maude-database-lacks-ai-specific-adverse-event-fields-creating-systematic-under-detection-of-ai-attributable-harm", "glp1-anhedonia-undermines-social-engagement-as-non-clinical-health-determinant", "glp1-anhedonia-tonic-receptor-occupancy-dose-dependent-reversible", "glp1-psychiatric-dose-response-data-absent-despite-mechanistic-evidence"]
+---
+
+# Anhedonia is absent from all GLP-1 adverse event labels despite 54,000+ trial participants because trials were not designed to measure hedonic outcomes
+
+The Washington Post reports that 'the drug has been studied in 54,000+ trial participants' yet 'anhedonia is NOT currently listed as adverse drug reaction or warning in any GLP-1 label.' Doctors interviewed state that 'reports of anhedonia are not widespread' despite researchers now compiling approximately 100 cases. This detection gap exists because clinical trials were designed to measure metabolic and cardiovascular endpoints, not hedonic capacity. The article notes no validated clinical instruments (like SHAPS, Snaith-Hamilton Pleasure Scale) are mentioned in prescribing practice, 'suggesting the field has not yet operationalized this as a monitorable adverse effect.' The systematic measurement gap means anhedonia could be significantly more prevalent than currently documented but remains invisible to both trial surveillance and post-market pharmacovigilance. This represents a structural regulatory oversight where trial design determines what adverse effects can be detected, and psychiatric outcomes were not prioritized in metabolic drug development.

domains/health/glp1-anhedonia-dose-dependent-reversible-weeks-tonic-suppression.md

@@ -0,0 +1,19 @@
+---
+type: claim
+domain: health
+description: Clinical case series shows anhedonia resolves in most patients within weeks when GLP-1 dose is reduced, with one documented case improving after 15mg→12.5mg tirzepatide reduction
+confidence: experimental
+source: Washington Post, multi-institution researcher compilation of ~100 cases
+created: 2026-05-08
+title: GLP-1-induced anhedonia is dose-dependent and reverses within weeks of dose reduction through tonic dopamine suppression rather than permanent neurological change
+agent: vida
+sourced_from: health/2026-04-16-washingtonpost-ozempic-personality-anhedonia-glp1.md
+scope: causal
+sourcer: Washington Post Health
+supports: ["glp1-anhedonia-tonic-receptor-occupancy-dose-dependent-reversible", "glp1-low-dose-psychiatric-protocol-prevents-anhedonia-through-ketogenic-pairing"]
+related: ["glp1-anhedonia-tonic-receptor-occupancy-dose-dependent-reversible", "glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "glp1-cns-effects-circuit-specific-reward-not-neurodegenerative", "glp1-low-dose-psychiatric-protocol-prevents-anhedonia-through-ketogenic-pairing"]
+---
+
+# GLP-1-induced anhedonia is dose-dependent and reverses within weeks of dose reduction through tonic dopamine suppression rather than permanent neurological change
+
+Researchers compiling approximately 100 cases of GLP-1-induced anhedonia report that 'most cases appeared to resolve with dose reduction often as quickly as within a few weeks.' One specific case documented a patient on Zepbound (tirzepatide) who reduced from 15mg to 12.5mg weekly and 'within two weeks reported feeling joy again.' The rapid reversibility timeframe (weeks, not months) combined with dose-response relationship suggests tonic receptor occupancy mechanism rather than permanent neurological adaptation. The proposed mechanism involves GLP-1 receptors in brainstem, lateral septum, and hypothalamus that 'tone down regions of the brain associated with pleasure.' Some persistent cases respond to bupropion (dopamine-enhancing antidepressant), supporting dopaminergic mediation. However, animal evidence is contradictory: one lab found 'chronically muted dopamine responses' while another found 'turbocharged' dopamine signal, indicating the precise mechanism remains unsettled. The clinical reversibility pattern distinguishes this from permanent structural changes and suggests anhedonia results from ongoing pharmacological suppression that lifts when drug exposure decreases.

domains/health/glp1-anhedonia-measurement-gap-creates-monitoring-blind-spot-for-most-reported-psychiatric-adverse-effect.md

@@ -11,9 +11,16 @@ sourced_from: health/2026-05-07-pmc-glp1-psychiatric-systematic-review-2026.md
 scope: structural
 sourcer: Sa et al. (2026)
 supports: ["glp1-trials-lack-validated-anhedonia-measurement-infrastructure"]
-related: ["fda-maude-database-lacks-ai-specific-adverse-event-fields-creating-systematic-under-detection-of-ai-attributable-harm", "glp1-anhedonia-tonic-receptor-occupancy-dose-dependent-reversible", "glp1-trials-lack-validated-anhedonia-measurement-infrastructure", "glp1-anhedonia-undermines-social-engagement-as-non-clinical-health-determinant", "glp1-psychiatric-dose-response-data-absent-despite-mechanistic-evidence", "glp1-psychiatric-effects-directionally-opposite-metabolic-versus-psychiatric-populations"]
+related: ["fda-maude-database-lacks-ai-specific-adverse-event-fields-creating-systematic-under-detection-of-ai-attributable-harm", "glp1-anhedonia-tonic-receptor-occupancy-dose-dependent-reversible", "glp1-trials-lack-validated-anhedonia-measurement-infrastructure", "glp1-anhedonia-undermines-social-engagement-as-non-clinical-health-determinant", "glp1-psychiatric-dose-response-data-absent-despite-mechanistic-evidence", "glp1-psychiatric-effects-directionally-opposite-metabolic-versus-psychiatric-populations", "glp1-anhedonia-measurement-gap-creates-monitoring-blind-spot-for-most-reported-psychiatric-adverse-effect"]
 ---
 
 # GLP-1 anhedonia measurement gap creates monitoring blind spot for most reported psychiatric adverse effect
 
 A comprehensive 38-study systematic review found that anhedonia data is 'ABSENT' from GLP-1 psychiatric literature despite being the most commonly reported psychiatric adverse effect in clinical practice. The review notes 'emotional blunting mentioned as potential adverse outcome but no incidence data. Anhedonia not characterized as distinct outcome.' This represents a genuine measurement infrastructure gap, not merely a knowledge gap. Standard depression scales (PHQ-9, HAM-D) used in GLP-1 trials do not isolate anhedonia as a distinct construct, and no GLP-1 trial has prospectively measured anhedonia using validated instruments like the Snaith-Hamilton Pleasure Scale. The clinical significance is that the most frequently reported psychiatric adverse effect is invisible to both clinical trials and pharmacovigilance systems. This creates a monitoring blind spot where patient-reported anhedonia cannot be systematically tracked, quantified, or correlated with dose, duration, or patient characteristics. The review's clinical recommendations include monthly psychiatric monitoring but provide no guidance on anhedonia assessment because no validated protocol exists.
+
+
+## Supporting Evidence
+
+**Source:** Washington Post 2026-04-16, FDA label review
+
+54,000+ trial participants studied but anhedonia not listed on any GLP-1 label. Article notes no validated clinical instruments (SHAPS) mentioned in prescribing practice, 'suggesting the field has not yet operationalized this as a monitorable adverse effect.'

domains/health/glp1-anhedonia-tonic-receptor-occupancy-dose-dependent-reversible.md

@@ -31,3 +31,10 @@ Systematic review of 80 RCTs (107,860 participants) finds 'direct evidence linki
 **Source:** Dr. Bosworth/Albright cohorts via Osmind
 
 Clinical evidence from ~100-patient cohorts shows 0.6mg weekly tirzepatide (quarter standard dose) produces no emotional blunting when paired with ketogenic diet. Supports dose-dependence mechanism and suggests ketogenic pairing may modulate anhedonic threshold.
+
+
+## Supporting Evidence
+
+**Source:** Washington Post 2026-04-16, multi-institution ~100 case compilation
+
+Washington Post documents specific case: patient reduced tirzepatide 15mg→12.5mg weekly, reported feeling joy again within two weeks. Researchers report 'most cases appeared to resolve with dose reduction often as quickly as within a few weeks.' Rapid reversibility timeframe (weeks) supports tonic suppression mechanism.

domains/health/glp1-anhedonia-undermines-social-engagement-as-non-clinical-health-determinant.md

@@ -10,26 +10,18 @@ agent: vida
 sourced_from: health/2026-05-05-ozempic-personality-anhedonia-glp1-dopamine.md
 scope: causal
 sourcer: Multiple (Washington Post, KTLA, Washington Times)
-challenges:
-- medical-care-explains-only-10-20-percent-of-health-outcomes-because-behavioral-social-and-genetic-factors-dominate-as-four-independent-methodologies-confirm
-related:
-- modernization-dismantles-family-and-community-structures-replacing-them-with-market-and-state-relationships-that-increase-individual-freedom-but-erode-psychosocial-foundations-of-wellbeing
-- modernization dismantles family and community structures replacing them with market and state relationships that increase individual freedom but erode psychosocial foundations of wellbeing
-- medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm
-- glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation
-- hedonic-eating-dopamine-circuit-adapts-to-glp1-suppression-explaining-continuous-delivery-requirement
-- glp1-anhedonia-tonic-receptor-occupancy-dose-dependent-reversible
-- glp1-prescribing-competency-gap-primary-care-psychiatric-monitoring
-supports:
-- Cultural narrative framing 'food noise quiet' as liberation delays recognition of GLP-1 dopamine suppression harm
-- GLP-1 clinical trials systematically lack validated hedonic measurement instruments making anhedonia invisible to regulatory infrastructure despite available tools like SHAPS
-- GLP-1 anhedonia measurement gap creates monitoring blind spot for most reported psychiatric adverse effect
-reweave_edges:
-- Cultural narrative framing 'food noise quiet' as liberation delays recognition of GLP-1 dopamine suppression harm|supports|2026-05-06
-- GLP-1 clinical trials systematically lack validated hedonic measurement instruments making anhedonia invisible to regulatory infrastructure despite available tools like SHAPS|supports|2026-05-07
-- GLP-1 anhedonia measurement gap creates monitoring blind spot for most reported psychiatric adverse effect|supports|2026-05-08
+challenges: ["medical-care-explains-only-10-20-percent-of-health-outcomes-because-behavioral-social-and-genetic-factors-dominate-as-four-independent-methodologies-confirm"]
+related: ["modernization-dismantles-family-and-community-structures-replacing-them-with-market-and-state-relationships-that-increase-individual-freedom-but-erode-psychosocial-foundations-of-wellbeing", "modernization dismantles family and community structures replacing them with market and state relationships that increase individual freedom but erode psychosocial foundations of wellbeing", "medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm", "glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "hedonic-eating-dopamine-circuit-adapts-to-glp1-suppression-explaining-continuous-delivery-requirement", "glp1-anhedonia-tonic-receptor-occupancy-dose-dependent-reversible", "glp1-prescribing-competency-gap-primary-care-psychiatric-monitoring", "glp1-anhedonia-undermines-social-engagement-as-non-clinical-health-determinant", "food-noise-quiet-narrative-reframes-glp1-anhedonia-as-liberation", "glp1-cns-efficacy-circuit-specific-reward-dopamine-success-neurodegeneration-failure"]
+supports: ["Cultural narrative framing 'food noise quiet' as liberation delays recognition of GLP-1 dopamine suppression harm", "GLP-1 clinical trials systematically lack validated hedonic measurement instruments making anhedonia invisible to regulatory infrastructure despite available tools like SHAPS", "GLP-1 anhedonia measurement gap creates monitoring blind spot for most reported psychiatric adverse effect"]
+reweave_edges: ["Cultural narrative framing 'food noise quiet' as liberation delays recognition of GLP-1 dopamine suppression harm|supports|2026-05-06", "GLP-1 clinical trials systematically lack validated hedonic measurement instruments making anhedonia invisible to regulatory infrastructure despite available tools like SHAPS|supports|2026-05-07", "GLP-1 anhedonia measurement gap creates monitoring blind spot for most reported psychiatric adverse effect|supports|2026-05-08"]
 ---
 
 # GLP-1 anhedonia mechanism undermines social engagement and meaning as non-clinical health determinants even while treating metabolic disease
 
-Clinicians are reporting a pattern they call 'Ozempic personality' where GLP-1 patients experience reduced interest not just in food but in social activities, sex, music, and other pleasurable activities. The mechanism is the same VTA dopamine circuit suppression that makes GLP-1 effective for addiction treatment — GLP-1 receptors in brain regions governing mood, motivation, and emotional responses inadvertently affect emotional engagement when altered. Patients describe 'emotional flattening' where they still recognize positive moments but feel less excitement or connection. This creates a paradox: GLP-1 may simultaneously treat metabolic disease (the clinical 10-20% of health determinants) while undermining the motivational substrate for social engagement and meaning (the behavioral/social 80-90%). The mechanism is supported by addiction research showing GLP-1 reduces craving preconsciously, indicating reward processing changes extend beyond food. No quantitative prevalence data exists yet — this is clinical pattern recognition phase with anecdotal reports from clinicians and social media. The FDA removed the suicidal behavior warning from GLP-1 in 2026 and no anhedonia warning exists, suggesting regulatory bodies are not yet tracking this risk.
+Clinicians are reporting a pattern they call 'Ozempic personality' where GLP-1 patients experience reduced interest not just in food but in social activities, sex, music, and other pleasurable activities. The mechanism is the same VTA dopamine circuit suppression that makes GLP-1 effective for addiction treatment — GLP-1 receptors in brain regions governing mood, motivation, and emotional responses inadvertently affect emotional engagement when altered. Patients describe 'emotional flattening' where they still recognize positive moments but feel less excitement or connection. This creates a paradox: GLP-1 may simultaneously treat metabolic disease (the clinical 10-20% of health determinants) while undermining the motivational substrate for social engagement and meaning (the behavioral/social 80-90%). The mechanism is supported by addiction research showing GLP-1 reduces craving preconsciously, indicating reward processing changes extend beyond food. No quantitative prevalence data exists yet — this is clinical pattern recognition phase with anecdotal reports from clinicians and social media. The FDA removed the suicidal behavior warning from GLP-1 in 2026 and no anhedonia warning exists, suggesting regulatory bodies are not yet tracking this risk.
+
+## Extending Evidence
+
+**Source:** Washington Post 2026-04-16, patient interviews
+
+Documented anhedonia extends beyond food to 'social activities, music, sex, and daily pleasures' — broad emotional blunting affecting all hedonic domains. One patient quote describes life feeling 'meh' across all previously enjoyable activities.

domains/health/glp1-cns-effects-circuit-specific-reward-not-neurodegenerative.md

@@ -10,19 +10,17 @@ agent: vida
 sourced_from: health/2026-05-07-jama-psychiatry-semaglutide-mdd-effort-decision.md
 scope: structural
 sourcer: Hartej Gill, University of Toronto
-related:
-- semaglutide-reduces-effort-cost-sensitivity-in-mdd-via-reward-circuit-engagement
-- glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation
-- semaglutide-produces-large-effect-aud-reduction-through-vta-dopamine-suppression
-- glp1-anhedonia-tonic-receptor-occupancy-dose-dependent-reversible
-- hedonic-eating-dopamine-circuit-adapts-to-glp1-suppression-explaining-continuous-delivery-requirement
-- glp1-anhedonia-undermines-social-engagement-as-non-clinical-health-determinant
-supports:
-- GLP-1 receptor agonist CNS efficacy is circuit-specific producing large effects in reward/dopamine-mediated conditions while failing in amyloid/tau-driven neurodegeneration
-reweave_edges:
-- GLP-1 receptor agonist CNS efficacy is circuit-specific producing large effects in reward/dopamine-mediated conditions while failing in amyloid/tau-driven neurodegeneration|supports|2026-05-08
+related: ["semaglutide-reduces-effort-cost-sensitivity-in-mdd-via-reward-circuit-engagement", "glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "semaglutide-produces-large-effect-aud-reduction-through-vta-dopamine-suppression", "glp1-anhedonia-tonic-receptor-occupancy-dose-dependent-reversible", "hedonic-eating-dopamine-circuit-adapts-to-glp1-suppression-explaining-continuous-delivery-requirement", "glp1-anhedonia-undermines-social-engagement-as-non-clinical-health-determinant", "glp1-cns-effects-circuit-specific-reward-not-neurodegenerative", "glp1-cns-efficacy-circuit-specific-reward-dopamine-success-neurodegeneration-failure", "semaglutide-fails-alzheimers-progression-despite-biomarker-effects-distinguishing-metabolic-prevention-from-neurodegeneration-treatment", "glp1-biomarker-improvement-without-clinical-benefit-demonstrates-surrogate-endpoint-limitation-in-neurodegeneration-trials"]
+supports: ["GLP-1 receptor agonist CNS efficacy is circuit-specific producing large effects in reward/dopamine-mediated conditions while failing in amyloid/tau-driven neurodegeneration"]
+reweave_edges: ["GLP-1 receptor agonist CNS efficacy is circuit-specific producing large effects in reward/dopamine-mediated conditions while failing in amyloid/tau-driven neurodegeneration|supports|2026-05-08"]
 ---
 
 # GLP-1 receptor agonists demonstrate circuit-specific CNS effects—efficacy in reward pathways but not neurodegenerative pathways
 
-The Gill MDD trial showing positive effects on effort-based decision-making (reward circuit function) combined with EVOKE/EVOKE-Plus Alzheimer's trial failures establishes a clear pattern: GLP-1 receptor agonists demonstrate efficacy in reward pathway disorders (major depression motivation deficits, alcohol use disorder) but not in neurodegenerative conditions. This circuit specificity maps to GLP-1 receptor distribution—high density in VTA, nucleus accumbens, and hypothalamus (reward/motivation circuits) but limited presence in cortical regions affected by neurodegeneration. The MDD trial's dissociation between failed executive function endpoint and successful effort-cost endpoint within the same study provides within-trial evidence of this specificity. This defines the therapeutic boundary for GLP-1 CNS applications: reward dysregulation conditions are viable targets, neurodegenerative conditions are not. The mechanism is receptor distribution, not general neuroprotection.
+The Gill MDD trial showing positive effects on effort-based decision-making (reward circuit function) combined with EVOKE/EVOKE-Plus Alzheimer's trial failures establishes a clear pattern: GLP-1 receptor agonists demonstrate efficacy in reward pathway disorders (major depression motivation deficits, alcohol use disorder) but not in neurodegenerative conditions. This circuit specificity maps to GLP-1 receptor distribution—high density in VTA, nucleus accumbens, and hypothalamus (reward/motivation circuits) but limited presence in cortical regions affected by neurodegeneration. The MDD trial's dissociation between failed executive function endpoint and successful effort-cost endpoint within the same study provides within-trial evidence of this specificity. This defines the therapeutic boundary for GLP-1 CNS applications: reward dysregulation conditions are viable targets, neurodegenerative conditions are not. The mechanism is receptor distribution, not general neuroprotection.
+
+## Supporting Evidence
+
+**Source:** Washington Post 2026-04-16, mechanism review
+
+Proposed mechanism: 'GLP-1 receptors in brainstem, lateral septum, and hypothalamus modulate neural pathways for food intake, reward, and energy. GLP-1s tone down regions of the brain associated with pleasure.' Circuit-specific reward suppression rather than global neurodegeneration.

domains/health/glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation.md

@@ -10,25 +10,10 @@ agent: vida
 sourced_from: health/2026-04-23-glp1-substance-use-disorder-33-trials.md
 scope: causal
 sourcer: PubMed/ClinicalTrials.gov systematic review
-challenges:
-- medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm
-related:
-- glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation
-- medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm
-- glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation
-- hedonic-eating-dopamine-circuit-adapts-to-glp1-suppression-explaining-continuous-delivery-requirement
-- behavioral-biological-health-dichotomy-false-for-reward-dysregulation-conditions
-- glp1-receptor-agonists-demonstrate-superior-efficacy-for-alcohol-use-disorder-in-comorbid-obesity-population
-- glp1-receptor-agonists-reduce-alcohol-use-disorder-risk-28-36-percent-across-5-26-million-patients
-- glp1-anhedonia-tonic-receptor-occupancy-dose-dependent-reversible
-supports:
-- The behavioral-biological health determinant dichotomy is false for obesity because what appears as behavioral overconsumption is dopamine reward dysregulation continuously activated by the food environment
-- Hedonic eating is mediated by dopamine reward circuits that adapt to GLP-1 suppression explaining both why GLP-1s work and why they require continuous delivery
-- GLP-1 receptor agonist CNS efficacy is circuit-specific producing large effects in reward/dopamine-mediated conditions while failing in amyloid/tau-driven neurodegeneration
-reweave_edges:
-- The behavioral-biological health determinant dichotomy is false for obesity because what appears as behavioral overconsumption is dopamine reward dysregulation continuously activated by the food environment|supports|2026-04-24
-- Hedonic eating is mediated by dopamine reward circuits that adapt to GLP-1 suppression explaining both why GLP-1s work and why they require continuous delivery|supports|2026-04-24
-- GLP-1 receptor agonist CNS efficacy is circuit-specific producing large effects in reward/dopamine-mediated conditions while failing in amyloid/tau-driven neurodegeneration|supports|2026-05-08
+challenges: ["medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm"]
+related: ["glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation", "medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm", "glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "hedonic-eating-dopamine-circuit-adapts-to-glp1-suppression-explaining-continuous-delivery-requirement", "behavioral-biological-health-dichotomy-false-for-reward-dysregulation-conditions", "glp1-receptor-agonists-demonstrate-superior-efficacy-for-alcohol-use-disorder-in-comorbid-obesity-population", "glp1-receptor-agonists-reduce-alcohol-use-disorder-risk-28-36-percent-across-5-26-million-patients", "glp1-anhedonia-tonic-receptor-occupancy-dose-dependent-reversible", "glp1-cns-efficacy-circuit-specific-reward-dopamine-success-neurodegeneration-failure", "glp1-cns-effects-circuit-specific-reward-not-neurodegenerative"]
+supports: ["The behavioral-biological health determinant dichotomy is false for obesity because what appears as behavioral overconsumption is dopamine reward dysregulation continuously activated by the food environment", "Hedonic eating is mediated by dopamine reward circuits that adapt to GLP-1 suppression explaining both why GLP-1s work and why they require continuous delivery", "GLP-1 receptor agonist CNS efficacy is circuit-specific producing large effects in reward/dopamine-mediated conditions while failing in amyloid/tau-driven neurodegeneration"]
+reweave_edges: ["The behavioral-biological health determinant dichotomy is false for obesity because what appears as behavioral overconsumption is dopamine reward dysregulation continuously activated by the food environment|supports|2026-04-24", "Hedonic eating is mediated by dopamine reward circuits that adapt to GLP-1 suppression explaining both why GLP-1s work and why they require continuous delivery|supports|2026-04-24", "GLP-1 receptor agonist CNS efficacy is circuit-specific producing large effects in reward/dopamine-mediated conditions while failing in amyloid/tau-driven neurodegeneration|supports|2026-05-08"]
 ---
 
 # GLP-1 receptor agonists may address multiple substance use disorders through shared mesolimbic dopamine circuit modulation with 33 clinical trials underway across alcohol opioid nicotine and cocaine use
@@ -172,4 +157,10 @@ Systematic review cites 29% alcohol reduction with dulaglutide and notes 'potent
 
 **Source:** Psychopharmacology Institute Q1 2026 Review
 
-Psychopharmacology Institute Q1 2026 guidance omits substance use disorder applications entirely, despite JAMA Psychiatry RCT evidence for AUD being available by Q1 2026. This suggests professional society guidance lags clinical evidence by approximately 1 year, creating a gap between published efficacy data and clinical practice recommendations.
+Psychopharmacology Institute Q1 2026 guidance omits substance use disorder applications entirely, despite JAMA Psychiatry RCT evidence for AUD being available by Q1 2026. This suggests professional society guidance lags clinical evidence by approximately 1 year, creating a gap between published efficacy data and clinical practice recommendations.
+
+## Extending Evidence
+
+**Source:** Washington Post 2026-04-16, researcher interviews
+
+Contradictory animal evidence on dopamine mechanism: one lab found 'chronically muted dopamine responses' while another found 'turbocharged' dopamine signal. Some persistent anhedonia cases treated with bupropion (dopamine-enhancing antidepressant) as compensatory treatment, supporting dopaminergic pathway but revealing mechanistic uncertainty.

domains/internet-finance/ninth-circuit-oral-argument-signals-pro-state-ruling-creating-circuit-split-with-third-circuit.md

@@ -46,3 +46,10 @@ Pre-argument analysis predicted Fourth Circuit will follow district court preced
 **Source:** Ninth Circuit oral argument, April 16, 2026
 
 Judge Nelson's 'That can't be a serious argument' response to the self-certification defense, combined with the panel's repeated questioning of swap classification and preemption scope, provides the strongest judicial signal yet that the Ninth Circuit will rule pro-state. The directness and strength of Nelson's skepticism—unusually blunt for appellate oral argument—suggests the panel has essentially decided.
+
+
+## Supporting Evidence
+
+**Source:** Fortune, April 20, 2026
+
+Fortune reports Ninth Circuit oral argument on April 16 showed apparent pro-state signals, with expected ruling June-August 2026 that would create explicit Third/Ninth circuit split. Massachusetts SJC oral argument May 4 also appeared skeptical of federal preemption, suggesting state authority becoming majority judicial view.

domains/internet-finance/third-circuit-ruling-creates-first-federal-appellate-precedent-for-cftc-preemption-of-state-gambling-laws.md

@@ -108,3 +108,10 @@ ZwillGen notes the Third Circuit's April 6 ruling gives Kalshi 'a tailwind going
 **Source:** Maryland district court ruling, Fourth Circuit oral argument schedule
 
 Maryland district court (August 2025) ruled against Kalshi using 'compliance coexistence' finding: Congress did not clearly intend to displace state gambling authority, and Kalshi could comply with both federal AND state law simultaneously. This directly contradicts Third Circuit's conflict preemption holding. Fourth Circuit oral argument May 7, 2026 will determine whether this becomes circuit-level precedent creating 2-circuit vs. 1-circuit split.
+
+
+## Supporting Evidence
+
+**Source:** Fortune, April 20, 2026
+
+Fortune mainstream business press coverage frames the Third Circuit April 6 ruling as the first step in a SCOTUS trajectory, signaling that prediction market regulation has crossed from crypto niche to top-tier regulatory issue receiving same treatment as CFTC/SEC crypto battles in 2022-2023. Polymarket pricing SCOTUS cert at 39% by year-end 2026 provides market-implied probability anchor.

domains/internet-finance/third-ninth-circuit-split-creates-scotus-pathway-for-prediction-market-preemption.md

@@ -11,7 +11,7 @@ sourced_from: internet-finance/2026-04-07-yogonet-third-circuit-kalshi-new-jerse
 scope: structural
 sourcer: Yogonet International
 supports: ["prediction-market-scotus-cert-likely-by-early-2027-because-three-circuit-litigation-pattern-creates-formal-split-by-summer-2026-and-34-state-amicus-participation-signals-federalism-stakes-justify-review"]
-related: ["ninth-circuit-kalshi-ruling-functions-as-coordinating-precedent-amplifying-regulatory-impact", "prediction-market-scotus-cert-likely-by-early-2027-because-three-circuit-litigation-pattern-creates-formal-split-by-summer-2026-and-34-state-amicus-participation-signals-federalism-stakes-justify-review", "38-state-ag-coalition-signals-prediction-market-federalism-not-partisanship", "third-circuit-ruling-creates-first-federal-appellate-precedent-for-cftc-preemption-of-state-gambling-laws", "cftc-licensed-dcm-preemption-protects-centralized-prediction-markets-but-not-decentralized-governance-markets", "third-ninth-circuit-split-creates-scotus-pathway-for-prediction-market-preemption", "third-circuit-dcm-field-preemption-excludes-decentralized-protocols-through-narrow-scope-definition"]
+related: ["ninth-circuit-kalshi-ruling-functions-as-coordinating-precedent-amplifying-regulatory-impact", "prediction-market-scotus-cert-likely-by-early-2027-because-three-circuit-litigation-pattern-creates-formal-split-by-summer-2026-and-34-state-amicus-participation-signals-federalism-stakes-justify-review", "38-state-ag-coalition-signals-prediction-market-federalism-not-partisanship", "third-circuit-ruling-creates-first-federal-appellate-precedent-for-cftc-preemption-of-state-gambling-laws", "cftc-licensed-dcm-preemption-protects-centralized-prediction-markets-but-not-decentralized-governance-markets", "third-ninth-circuit-split-creates-scotus-pathway-for-prediction-market-preemption", "third-circuit-dcm-field-preemption-excludes-decentralized-protocols-through-narrow-scope-definition", "ninth-circuit-oral-argument-signals-pro-state-ruling-creating-circuit-split-with-third-circuit", "ninth-circuit-sjc-simultaneous-skepticism-signals-state-authority-becoming-majority-judicial-view"]
 ---
 
 # The 3rd/9th Circuit split on CFTC preemption creates near-certain SCOTUS review, with the outcome determining whether state gambling law can reach federally-registered prediction market platforms
@@ -45,3 +45,10 @@ Third Circuit (New Jersey) now sides with CFTC preemption in a 2-1 decision, whi
 **Source:** InGame, April 16 2026 Ninth Circuit oral argument
 
 Ninth Circuit judge's April 16 dismissive comment ('This can't be a serious argument') provides concrete oral argument evidence that the circuit split is materializing. Combined with Massachusetts SJC's 'swimming upstream' comment on same issue, two separate courts used dismissive language toward prediction market companies in the same week, creating a pattern of judicial hostility outside the Third Circuit.
+
+
+## Extending Evidence
+
+**Source:** Fortune, April 20, 2026
+
+Fortune identifies projected SCOTUS cert petition timeline of July-September 2026 following expected Ninth Circuit pro-state ruling. Mainstream business press framing this as 'one of the most significant Supreme Court cases for the prediction market industry' elevates regulatory stakes beyond specialist discourse.

domains/space-development/SpaceX vertical integration across launch broadband and manufacturing creates compounding cost advantages that no competitor can replicate piecemeal.md

@@ -104,3 +104,10 @@ Terafab announced March 21, 2026 extends SpaceX's vertical integration into semi
 **Source:** Bloomberg, Motley Fool, TechStackIPO reporting on SpaceX S-1 filing, May 2026
 
 SpaceX's June 2026 IPO targets above $2 trillion valuation with $75B raise, representing a 95x+ revenue multiple. The valuation explicitly prices in the full flywheel thesis: Starship economics → Starlink revenue → xAI monetization → Terafab fabrication. The $55B Texas Terafab filing as part of IPO disclosures reveals the semiconductor fabrication layer completing the atoms-to-bits vertical integration stack.
+
+
+## Challenging Evidence
+
+**Source:** Reuters S-1 analysis, April 2026
+
+SpaceX's 2025 financials show the vertical integration flywheel is now stressed by capital demands that exceed its organic cash generation. Starlink generates $3B FCF but xAI alone burns $10B/year, creating a 3x deficit. The company went from $8B profit in 2024 to $5B loss in 2025 post-xAI acquisition. This suggests the compounding cost advantages have a ceiling—they generate operational efficiency but cannot self-fund unlimited capital-intensive expansions like AI infrastructure and semiconductor fabrication.

domains/space-development/spacex-1m-odc-filing-represents-vertical-integration-at-unprecedented-scale-creating-captive-starship-demand-200x-starlink.md

@@ -45,3 +45,10 @@ Terafab's 80% orbital compute allocation provides the semiconductor supply chain
 **Source:** SpaceX S-1 April 2026
 
 The S-1 viability warning undermines the vertical integration thesis: SpaceX's legal disclosure states orbital AI data centers 'may not achieve commercial viability' due to unsolved engineering challenges (radiation hardening, thermal management, repair infeasibility, continuous power). If the orbital data center thesis fails, the captive Starship demand evaporates, the Terafab investment ($25B with 80% orbital earmark) is stranded, and the xAI acquisition rationale collapses. The vertical integration advantage only holds if the integrated product is viable.
+
+
+## Extending Evidence
+
+**Source:** Reuters S-1 financial analysis, April 2026
+
+The 1M satellite filing's timing (April 2026, same month as S-1 filing) and scale now appear as IPO justification rather than pure operational plan. SpaceX needs to raise $75B to fund a $15-20B annual capital gap between Starlink's $3B FCF and combined requirements from xAI ($10B/year), Terafab ($5B/year), and Starship development. The 1M constellation creates the captive demand narrative that justifies this unprecedented capital raise.

domains/space-development/spacex-xai-acquisition-transformed-profitable-company-into-structural-loss-making-ipo-financially-necessary.md

@@ -0,0 +1,20 @@
+---
+type: claim
+domain: space-development
+description: The xAI acquisition in February 2026 fundamentally changed SpaceX's financial profile from $8B profit (2024) to $5B loss (2025), with xAI burning $10B/year while Starlink generates only $3B free cash flow
+confidence: experimental
+source: Reuters S-1 analysis, April 2026
+created: 2026-05-08
+title: SpaceX's xAI acquisition transformed a profitable company into one running $5B annual losses, making the 2026 IPO financially necessary rather than a liquidity event
+agent: astra
+sourced_from: space-development/2026-04-24-reuters-spacex-ai-burning-starlink-cash.md
+scope: structural
+sourcer: Reuters
+supports: ["spacex-1m-odc-filing-represents-vertical-integration-at-unprecedented-scale-creating-captive-starship-demand-200x-starlink", "terafab-extends-spacex-vertical-integration-into-semiconductor-fabrication-creating-atoms-to-bits-stack-spanning-launch-broadband-ai-chips-and-orbital-computing"]
+challenges: ["SpaceX vertical integration across launch broadband and manufacturing creates compounding cost advantages that no competitor can replicate piecemeal"]
+related: ["SpaceX vertical integration across launch broadband and manufacturing creates compounding cost advantages that no competitor can replicate piecemeal"]
+---
+
+# SpaceX's xAI acquisition transformed a profitable company into one running $5B annual losses, making the 2026 IPO financially necessary rather than a liquidity event
+
+SpaceX's 2025 financial results reveal a dramatic transformation in the company's economic structure following the xAI acquisition. In 2024, SpaceX was profitable with approximately $8B in net income. In 2025, after acquiring xAI in February 2026, the company posted a $5B consolidated net loss despite revenue growth to $18.5B. The core driver is xAI's extraordinary burn rate of $28M/day ($10.2B annually), which exceeds Starlink's $3B free cash flow by more than 3x. Starlink remains the only profitable segment, generating $11.4B revenue at 63% adjusted EBITDA margins. However, this profit engine now subsidizes three massive capital consumers: xAI operations ($10B/year), Starship development (multi-billion annually), and the newly announced Terafab commitment ($25B over ~5 years, or $5B/year). The arithmetic is stark: $3B organic free cash flow against $15-20B in annual capital requirements. The April 2026 IPO filing, coming just two months after the xAI acquisition closed, suggests the IPO was always the planned financing mechanism to absorb xAI's burn rate. This reframes the IPO from a market access event to a structural financial necessity—without it, the combined entity cannot fund its stated ambitions.

domains/space-development/starlink-profit-engine-subsidizes-three-capital-drains-creating-ipo-dependency-for-terafab-and-orbital-ai.md

@@ -0,0 +1,19 @@
+---
+type: claim
+domain: space-development
+description: The capital allocation arithmetic reveals Starlink generates $3B FCF while xAI burns $10B/year, Terafab requires $5B/year, and Starship development continues at multi-billion annual rates—a 5-7x gap that only IPO proceeds can close
+confidence: experimental
+source: Reuters S-1 financial analysis, April 2026
+created: 2026-05-08
+title: Starlink's $3B annual free cash flow must subsidize $15-20B in combined annual capital deployment across xAI, Terafab, and Starship, making IPO proceeds structurally required for orbital AI ambitions
+agent: astra
+sourced_from: space-development/2026-04-24-reuters-spacex-ai-burning-starlink-cash.md
+scope: structural
+sourcer: Reuters
+supports: ["spacex-1m-odc-filing-represents-vertical-integration-at-unprecedented-scale-creating-captive-starship-demand-200x-starlink", "terafab-extends-spacex-vertical-integration-into-semiconductor-fabrication-creating-atoms-to-bits-stack-spanning-launch-broadband-ai-chips-and-orbital-computing"]
+related: ["orbital-data-center-economics-face-decade-long-cost-parity-gap-with-terrestrial-compute-through-mid-2030s", "spacex-1m-odc-filing-represents-vertical-integration-at-unprecedented-scale-creating-captive-starship-demand-200x-starlink", "terafab-extends-spacex-vertical-integration-into-semiconductor-fabrication-creating-atoms-to-bits-stack-spanning-launch-broadband-ai-chips-and-orbital-computing"]
+---
+
+# Starlink's $3B annual free cash flow must subsidize $15-20B in combined annual capital deployment across xAI, Terafab, and Starship, making IPO proceeds structurally required for orbital AI ambitions
+
+SpaceX's 2025 financials expose a fundamental capital allocation problem that makes the IPO a prerequisite for the company's stated ambitions rather than an optional financing event. Starlink, the only profitable business segment, generates approximately $3B in annual free cash flow from $11.4B revenue at 63% adjusted EBITDA margins. Against this, the company faces three massive capital consumers: (1) xAI operations burning $28M/day or $10.2B annually post-acquisition, (2) Terafab's $25B commitment over approximately 5 years ($5B/year), and (3) ongoing Starship development consuming multi-billion dollars annually (historically $15B+ total, suggesting $3-5B/year current run rate). The total annual capital requirement is $18-20B against $3B in organic free cash flow—a 6-7x gap. This arithmetic makes the $75B IPO fundraise not a liquidity event but a structural necessity. Without it, neither Terafab nor the orbital AI data center constellation can proceed as planned. The timing is revealing: the S-1 was filed in April 2026, just two months after the xAI acquisition closed in February 2026, suggesting the IPO was always the planned mechanism to finance the combined entity's capital-intensive roadmap. This reframes the entire orbital AI strategy as IPO-contingent rather than organically fundable.

domains/space-development/terafab-extends-spacex-vertical-integration-into-semiconductor-fabrication-creating-atoms-to-bits-stack-spanning-launch-broadband-ai-chips-and-orbital-computing.md

@@ -11,9 +11,16 @@ sourced_from: space-development/2026-03-21-musk-terafab-tesla-spacex-xai-chip-fa
 scope: structural
 sourcer: Teslarati, Fortune, EE Times
 supports: ["orbital-data-centers-and-space-based-solar-power-share-identical-infrastructure-requirements-creating-dual-use-revenue-bridge", "spacex-1m-odc-filing-represents-vertical-integration-at-unprecedented-scale-creating-captive-starship-demand-200x-starlink"]
-related: ["SpaceX vertical integration across launch broadband and manufacturing creates compounding cost advantages that no competitor can replicate piecemeal", "the atoms-to-bits spectrum positions industries between defensible-but-linear and scalable-but-commoditizable with the sweet spot where physical data generation feeds software that scales independently"]
+related: ["SpaceX vertical integration across launch broadband and manufacturing creates compounding cost advantages that no competitor can replicate piecemeal", "the atoms-to-bits spectrum positions industries between defensible-but-linear and scalable-but-commoditizable with the sweet spot where physical data generation feeds software that scales independently", "terafab-extends-spacex-vertical-integration-into-semiconductor-fabrication-creating-atoms-to-bits-stack-spanning-launch-broadband-ai-chips-and-orbital-computing"]
 ---
 
 # Terafab extends SpaceX vertical integration into semiconductor fabrication creating an atoms-to-bits stack spanning launch broadband AI chips and orbital computing that no competitor can replicate piecemeal
 
 Terafab announced March 21, 2026 is a $25 billion joint venture between Tesla, SpaceX, and xAI (acquired by SpaceX in February 2026) to build a vertically integrated semiconductor facility at Giga Texas North Campus. The facility consolidates chip design, lithography, fabrication, memory production, advanced packaging, and testing under one roof with target output exceeding 1 terawatt of AI compute capacity per year. Intel joined April 7, 2026 bringing 18A process node capability. The product split allocates 80% of compute to space-based orbital AI satellites using custom D3 chips designed for orbital environments, and 20% to ground-based applications including Tesla vehicles and Optimus robots using AI4 and AI5 chips. This extends SpaceX's existing vertical integration flywheel from launch (Raptor engines, Starship) and broadband (Starlink) into semiconductor manufacturing and orbital computing infrastructure. The atoms-to-bits integration is now literal: Terafab produces chips, chips go into orbital satellites launched by Starship, satellites collect and process data, data improves software, software improves chip design. No competitor operates across this full stack - traditional semiconductor companies don't launch satellites, satellite operators don't manufacture chips, and AI companies don't control launch vehicles. The 80% orbital allocation ties directly to SpaceX's January 2026 FCC filing for up to one million satellites as an orbital data center constellation, with each satellite providing 100 kilowatts of power for onboard AI processors. The vertical integration creates captive demand for Starship launches (200x Starlink scale based on satellite count), eliminates chip supply chain dependencies, and enables co-design of hardware for the orbital radiation and thermal environment.
+
+
+## Extending Evidence
+
+**Source:** Reuters S-1 analysis, April 2026
+
+Terafab's $25B commitment ($5B/year over ~5 years) is only financeable through IPO proceeds. SpaceX's organic free cash flow from Starlink is $3B/year, while total capital requirements across xAI, Terafab, and Starship are $18-20B/year. This makes the semiconductor vertical integration contingent on successful IPO execution—it's not self-funding from the existing flywheel.

inbox/archive/health/2026-04-16-washingtonpost-ozempic-personality-anhedonia-glp1.md

@@ -7,10 +7,13 @@ date: 2026-04-16
 domain: health
 secondary_domains: []
 format: article
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-05-08
 priority: high
 tags: [GLP-1, semaglutide, anhedonia, ozempic-personality, dopamine, reward, side-effects, dose-dependence, reversibility]
 intake_tier: research-task
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content

inbox/archive/internet-finance/2026-04-20-fortune-kalshi-scotus-prediction-markets-path.md

@@ -7,10 +7,13 @@ date: 2026-04-20
 domain: internet-finance
 secondary_domains: []
 format: article
-status: unprocessed
+status: processed
+processed_by: rio
+processed_date: 2026-05-08
 priority: medium
 tags: [prediction-markets, kalshi, scotus, supreme-court, circuit-split, third-circuit, ninth-circuit, event-contracts]
 intake_tier: research-task
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content

inbox/archive/space-development/2026-04-24-reuters-spacex-ai-burning-starlink-cash.md

@@ -7,10 +7,13 @@ date: 2026-04-24
 domain: space-development
 secondary_domains: [manufacturing]
 format: article
-status: unprocessed
+status: processed
+processed_by: astra
+processed_date: 2026-05-08
 priority: high
 tags: [spacex, starlink, xai, financials, capital-allocation, ipo, belief-7, single-player, atoms-to-bits]
 intake_tier: research-task
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content